Mycobacterium tuberculosis infections in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 68-76

  Subramanian, A K ^a   Morris, M I ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI HEALTH SYSTEM   (United States)

Author keywords

Latent infection; Mycobacterium tuberculosis; PPD; prevention; tuberculous

Indexed keywords

AMIKACIN; BCG VACCINE; CAPREOMYCIN; CYCLOSERINE; CYCLOSPORIN; ETHAMBUTOL; ETHIONAMIDE; EVEROLIMUS; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; PYRIDOXINE; QUINOLONE DERIVATIVE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TACROLIMUS;

ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CYTOPENIA; DIARRHEA; DISEASE TRANSMISSION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS; HUMAN; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOTHYROIDISM; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; INTERSTITIAL NEPHRITIS; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TRANSPLANTATION; MEDICAL DOCUMENTATION; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NEUROTOXICITY; OPTIC NEURITIS; ORGAN TRANSPLANTATION; OTOTOXICITY; PERIPHERAL NEUROPATHY; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RED ORANGE BODY FLUID; RED ORANGE COLORED BODY FLUID; SEIZURE; SIDE EFFECT; TENDINITIS; TUBERCULIN TEST; TUBERCULOSIS; VISUAL IMPAIRMENT;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; ORGAN TRANSPLANTATION; TUBERCULOSIS;

EID: 84874831590     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12100     Document Type: Article

References (70)

1. Munoz P, Rodriguez C, Bouza E,. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40: 581-587.
2. Singh N, Paterson DL,. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998; 27: 1266-1277.
3. Currie AC, Knight SR, Morris PJ,. Tuberculosis in renal transplant recipients: The evidence for prophylaxis. Transplantation 2010; 90: 695-704.
4. Ginsberg AM, Spigelman M,. Challenges in tuberculosis drug research and development. Nat Med 2007; 13: 290-294.
5. Dorman SE, Chaisson RE,. From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis. Nat Med 2007; 13: 295-298.
6. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
7. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
8. Subramanian A, Dorman S,. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S57-S62.
9. Young J-A WD,. Typical and atypical Mycobacterium infections after hematopoietic stem cell or solid organ transplantation. In: Bowden RA, Snydman DR, eds. Transplant infections. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins, 2010, pp. 195-203.
10. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: Consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-1284.
11. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: Incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-1665.
12. Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005; 7: 99-108.
13. Agarwal SK, Gupta S, Dash SC, Bhowmik D, Tiwari SC,. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. Int Urol Nephrol 2004; 36: 425-431.
14. Naqvi R, Akhtar S, Noor H, et al. Efficacy of isoniazid prophylaxis in renal allograft recipients. Transplant Proc 2006; 38: 2057-2058.
15. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63: 1278-1286.
16. Benito N, Sued O, Moreno A, et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74: 1381-1386.
17. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections. Tuberculosis. Nephrol Dial Transplant 2002; 17(Suppl 4): 39-43.
18. Yehia BR, Blumberg EA,. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl 2010; 16: 1129-1135.
19. Clemente WT, Faria LC, Lima SS, et al. Tuberculosis in liver transplant recipients: A single Brazilian center experience. Transplantation 2009; 87: 397-401.
20. Zhang XF, Lv Y, Xue WJ, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: Experience from a single center in China. Transplant Proc 2008; 40: 1382-1385.
21. Bravo C, Roldan J, Roman A, et al. Tuberculosis in lung transplant recipients. Transplantation 2005; 79: 59-64.
22. Wang B, Lu Y, Yu L, Liu C, Wu Z, Pan C,. Diagnosis and treatment for tuberculosis infection in liver transplant recipients: Case reports. Transplant Proc 2007; 39: 3509-3511.
23. Kaaroud H, Beji S, Boubaker K, et al. Tuberculosis after renal transplantation. Transplant Proc 2007; 39: 1012-1013.
24. Hsu MS, Wang JL, Ko WJ, et al. Clinical features and outcome of tuberculosis in solid organ transplant recipients. Am J Med Sci 2007; 334: 106-110.
25. Chou NK, Wang JL, Chi NH, et al. Tuberculosis after heart transplantation: Twenty years of experience in a single center in Taiwan. Transplant Proc 2008; 40: 2631-2633.
26. Ruangkanchanasetr P, Natejumnong C, Kitpanich S, Chaiprasert A, Luesutthiviboon L, Supaporn T,. Prevalence and manifestations of tuberculosis in renal transplant recipients: A single-center experience in Thailand. Transplant Proc 2008; 40: 2380-2381.
27. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS,. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996; 61: 211-215.
28. Lopez de Castilla D, Schluger NW,. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12: 106-112.
29. Holty JE, Sista RR,. Mycobacterium tuberculosis infection in transplant recipients: Early diagnosis and treatment of resistant tuberculosis. Curr Opin Organ Transplant 2009; 14: 613-618.
30. Transplantation-transmitted tuberculosis-Oklahoma and Texas, 2007; MMWR Recomm Rep 2008; 57: 333-336.
31. Ison MG, Nalesnik MA,. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123-1130.
32. Winthrop KL, Kubak BM, Pegues DA, et al. Transmission of mycobacterium tuberculosis via lung transplantation. Am J Transplant 2004; 4: 1529-1533.
33. Ison MG, Hager J, Blumberg E, et al. Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009; 9: 1929-1935.
34. Sundberg R, Shapiro R, Darras F, et al. A tuberculosis outbreak in a renal transplant program. Transplant Proc 1991; 23: 3091-3092.
35. Jereb JA, Burwen DR, Dooley SW, et al. Nosocomial outbreak of tuberculosis in a renal transplant unit: Application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis 1993; 168: 1219-1224.
36. Torres J, Aguado JM, San Juan R, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: Experience with kidney transplantation. Transpl Int 2008; 21: 873-878.
37. Lattes R, Radisic M, Rial M, Argento J, Casadei D,. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999; 1: 98-104.
38. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K,. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
39. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747.
40. Sester U, Wilkens H, van Bentum K, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J 2009; 34: 702-710.
41. Lange B, Vavra M, Kern WV, Wagner D,. Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients. The Eur Respir J 2010; 35: 1179-1182.
42. Pai M, Zwerling A, Menzies D,. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008; 149: 177-184.
43. Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7: 2797-2801.
44. Rubin RH,. Infection in the organ transplant recipient. In:, Rubin RH, ed. Clinical Approach to infection in the compromised host. New York and London: Plenum, 2002, pp. 573-650.
45. Casas S, Munoz L, Moure R, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl 2011; 17: 1205-1211.
46. Theodoropoulos N, Lanternier F, Rassiwala J, et al. Use of the QuantiFERON-TB Gold interferon-gamma release assay for screening transplant candidates: A single-center retrospective study. Transpl Infect Dis 2012; 14: 1-8.
47. Kim SH, Lee SO, Park IA, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010; 12: 113-119.
48. Kim SH, Lee SO, Park JB, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011; 11: 1927-1935.
49. Lyu J, Lee SG, Hwang S, et al. Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver Transpl 2011; 17: 963-968.
50. Herrera V, Perry S, Parsonnet J, Banaei N,. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 2011; 52: 1031-1037.
51. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180: 49-58.
52. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49: 1-51.
53. Blumberg HM, Leonard MK Jr., Jasmer RM,. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293: 2776-2784.
54. Menzies D, Al Jahdali H, Al Otaibi B,. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-66.
55. Jafri SM, Singal AG, Kaul D, Fontana RJ,. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl 2011; 17: 306-314.
56. Thomas PA Jr., Mozes MF, Jonasson O,. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979; 114: 597-599.
57. Schluger LK, Sheiner PA, Jonas M, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63: 364-369.
58. Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM,. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis 1973; 107: 523-529.
59. Antony SJ, Ynares C, Dummer JS,. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11: 34-37.
60. Singh N, Wagener MM, Gayowski T,. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74: 892-895.
61. Jahng AW, Tran T, Bui L, Joyner JL,. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83: 1557-1562.
62. Aspler A, Long R, Trajman A, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65: 582-587.
63. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
64. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60: 1650-1653.
65. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ,. Tuberculosis in liver transplant recipients: A systematic review and meta-analysis of individual patient data. Liver Transpl 2009; 15: 894-906.
66. Torre-Cisneros J, Caston JJ, Moreno J, et al. Tuberculosis in the transplant candidate: Importance of early diagnosis and treatment. Transplantation 2004; 77: 1376-1380.
67. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM,. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 1153-1158.
68. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467.
69. Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL,. Tuberculosis in renal transplant recipients: Rifampicin sparing treatment protocol. Int Urol Nephrol 2002; 34: 551-553.
70. Jha V, Sakhuja V, Gupta D, et al. Successful management of pulmonary tuberculosis in renal allograft recipients in a single center. Kidney Int 1999; 56: 1944-1950.